- Home
- ALEC
ALEC
Alector Inc.
as 04-25-2025 4:00pm EST
Alector Inc is a clinical-stage biopharmaceutical company. It is engaged in developing a novel therapeutic approach for the treatment of neurodegeneration. The firm is involved in developing therapies that are designed to simultaneously counteract pathologies by restoring healthy immune function to the brain. Its pipeline products include AL001, AL002, AL003, and AL101.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 101.1M | IPO Year: | 2019 |
| Target Price: | $4.10 | AVG Volume (30 days): | 809.4K |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.87 - $6.78 | Next Earning Date: | 05-07-2025 |
| Revenue: | $100,558,000 | Revenue Growth: | 3.60% |
| Revenue Growth (this year): | -89.15% | Revenue Growth (next year): | 376.51% |
Stock Insider Trading Activity of Alector Inc. (ALEC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Rosenthal Arnon | ALEC | Chief Executive Officer | Mar 3 '25 | Sell | $1.47 | 40,330 | $59,176.21 | 2,466,744 | |
| Romano Gary | ALEC | Chief Medical Officer | Mar 3 '25 | Sell | $1.47 | 16,306 | $23,927.42 | 332,977 | |
| GRASSO MARC | ALEC | Chief Financial Officer | Mar 3 '25 | Sell | $1.47 | 18,091 | $26,546.73 | 312,560 | |
| Kenkare-Mitra Sara | ALEC | President and Head of R&D | Mar 3 '25 | Sell | $1.47 | 29,073 | $42,661.72 | 536,142 |
Latest Alector Inc. News
ALEC Breaking Stock News: Dive into ALEC Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
5 days ago
Alector concludes enrolment in Phase II trial of Alzheimer’s treatment
MT Newswires
9 days ago
Alector Completes Enrollment for Phase 2 Alzheimer's Trial of AL101
GlobeNewswire
9 days ago
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease
MT Newswires
a month ago
Alector Appoints New Chief Medical Officer
GlobeNewswire
a month ago
Alector Provides Executive Leadership Update
Simply Wall St.
2 months ago
Alector Full Year 2024 Earnings: Beats Expectations
Thomson Reuters StreetEvents
2 months ago
Q4 2024 Alector Inc Earnings Call
GuruFocus.com
2 months ago
Alector Inc (ALEC) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ...
Compare ALEC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALEC Alector Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.